The M&A and Life Sciences teams advised Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) on its definitive agreement under which ONO Pharmaceutical Co., Ltd. (ONO) will acquire Deciphera for $25.60 per share in cash, which represents a total equity value of $2.4 billion.
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK® is Deciphera's switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK® is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States.
The Goodwin team was led by Stuart Cable, Richard Hoffman, Lisa Haddad and James Ding and included Peter Moorman, Benjamin Colao, Jason Wu, Hyun Lee, Sarah Ashfaq, Alicia Tschirhart, Bonnie Choi, Swetha Gopalakrishnan, Gregory Gutierrez, Theresa Kavanaugh, Jessica Rothstein, Sarah Bock, Grace Wirth, Morgan Frisoli, Benjamin Kurrass, Kristopher Ring, Zhe Yang, Tim Worden, Susan Lee, Roger Cohen, Heath Roosevelt Ingram, Lucy Sharples, Luke Nauth, Andy Lacy, Sarah Jordan, Eram Khan, Elliot Silver, Brady Cummins, Anuj Ghai, Alex Jobson, Caroline Bullerjahn, Christina Lewis, Alastair Papworth, Jacqueline Klosek, Frederica De Santis, Jacob Lee, Daniel Karelitz, Leon Peschel, Jacob Osborn, Justin Pierce, Gozde Guckaya, Nathan Brodeur and Cecelia Lockner.
For more details, read the press release.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.